Pharmacovigilance – Webinars and Online Events

This on-demand webinar explores how an electron-activated dissociation (EAD)-based LC-MS workflow provides a comprehensive approach to glycan analysis, enabling more accurate profiling and streamlined processes.

This webinar explores the implementation of a liquid chromatography mass spectrometry (LC-MS) workflow for peptide mapping to investigate and track these PTMs.

This webinar highlights innovative solutions to these challenges, Ebru Selin Sele offers her insights into advanced methodologies for more efficient and accurate metabolite identification.

In this webinar, we will explore how retinal organoids are used as a platform to assess the safety and efficacy of retinal gene therapy treatments.

Non-alcoholic fatty liver disease (NAFLD) is a spectrum of metabolic disorders that affects 25% of our global population. 20% of those with NAFLD develop non-alcoholic steatohepatitis (NASH), which can result in cirrhosis and liver cancer.

Despite continued research and development efforts, not one NASH therapeutic agent has made it to market yet. Traditional preclinical tests have repeatedly failed to predict human drug efficacy as they inadequately recreate the complexity and multifaceted nature of this human disease. As a result, NASH is poised to become a global health and economic burden.

Is it time to increase your chances of clinical success with a new human-relevant approach to drug discovery and development?

In this webinar you will learn how the power of large-scale proteomics can be leveraged for multiple divergent applications in the field of oncology.

Pharmaceutical compounds need to undergo safety assessment screening. These in vitro frontline screening assays should be multi-parametric, scalable and mechanistic enabling a high degree of predictivity and specificity.

Pharmaceutical compounds need to undergo safety assessment screening. These in vitro frontline screening assays should be multi-parametric, scalable and mechanistic enabling a high degree of predictivity and specificity.

In this webinar, we will summarise the current literature on non-invasive VNS in Parkinson’s disease and discuss preliminary findings of its therapeutic potential with an emphasis on its efficacy in improving cognitive and gait control in people with Parkinson’s.

Don't miss this 2-day interactive online event where the experts will be discussing current challenges in safety pharmacology and cardiac physiology, in silico modeling and best practices and evolvements of safety pharmacology methods.